

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

CLAIMS

What is claimed is:

1) 9

1.

A method of enhancing paracellular permeability at an absorption site in a subject, the method comprising:

5

a) administering an effective amount of a phospholipase C inhibitor to a subject at a time in which enhanced paracellular permeability is desired; and

1) 9

b) enhancing paracellular permeability in the subject at the absorption site through the administering of the effective amount of the phospholipase C inhibitor.

10

2. The method of claim 1, wherein the phospholipase C inhibitor is selected from the group consisting of an alkylphosphocholine, a 3-nitrocoumarin or derivative thereof, a 3-cyanocoumarin or derivative thereof, a 3-halocoumarin or derivative thereof, a 3-acetoxycoumarin or derivative thereof, a coumarin-3-sulfonic acid or derivative thereof, and an N-alkylsuccinimido steroid derivative.

15

3. The method of claim 2, wherein the alkylphosphocholine further comprises an alkyl chain of ten to twenty methylene groups.

20

4. The method of claim 2, wherein the 3-halocoumarin is 3-fluorocoumarin or derivative thereof, 3-chlorocoumarin or derivative thereof, or 3-iodocoumarin or derivative thereof.

5. The method of claim 2, wherein the N-alkylsuccinimido steroid derivative comprises an alkyl chain of one to ten methylene groups.

25

6. The method of claim 1, wherein the absorption site comprises intestinal epithelium.

~~7.~~

8.

9.

10

14

12

13. The method of claim 10, wherein the N-alkylsuccinimido steroid derivative comprises an alkyl chain of one to ten methylene groups.

14. The method of claim 9, wherein the absorption site comprises intestinal epithelium.

5 15. The method of claim 9, wherein the absorption site comprises the blood brain barrier.

16. The method of claim 9, wherein the phospholipase C inhibitor is formulated for oral, buccal, nasal, rectal or transdermal administration, or in a form suitable to contact colonic epithelium, or in a form suitable for administration by inhalation or insufflation.

10 17. A composition comprising:

- a) a hydrophilic drug;
- b) a phospholipase C inhibiting amount of a phospholipase C inhibitor; and
- 15 c) a pharmaceutically acceptable carrier.

18. The composition of claim 17, wherein the phospholipase C inhibitor is selected from the group consisting of an alkylphosphocholine, a 3-nitrocoumarin or derivative thereof, a 3-cyanocoumarin or derivative thereof, a 3-halocoumarin or derivative thereof, a 3-acetoxycoumarin or derivative thereof, a coumarin-3-sulfonic acid or derivative thereof, and an N-alkylsuccinimido steroid derivative.

19. The composition of claim 18, wherein the alkylphosphocholine further comprises an alkyl chain of ten to twenty methylene groups.

FOOTNOTES

112 20. The method of claim 18, wherein the 3-halocoumarin is 3-fluorocoumarin or derivative thereof, 3-chlorocoumarin or derivative thereof, or 3-iodocoumarin or derivative thereof.

112 21. The method of claim 18, wherein the N-alkylsuccinimido steroid derivative comprises an alkyl chain of one to ten methylene groups.

5 22. A method of preparing a composition that facilitates oral availability of a hydrophilic drug to a subject in need thereof, the method comprising:

- 10 a) providing a hydrophilic drug;
- b) providing a phospholipase C inhibitor; and
- c) mixing the hydrophilic drug and a phospholipase C inhibiting amount of the phospholipase C inhibitor with a pharmaceutically acceptable carrier, whereby a composition that facilitates oral availability of the hydrophilic drug is prepared.

15 23. The method of claim 22, wherein the phospholipase C inhibitor is selected from the group consisting of an alkylphosphocholine, a 3-nitrocoumarin or derivative thereof, a 3-cyanocoumarin or derivative thereof, a 3-halocoumarin or derivative thereof, a 3-acetoxycoumarin or derivative thereof, a coumarin-3-sulfonic acid or derivative thereof, and an N-alkylsuccinimido steroid derivative.

20 24. The method of claim 23, wherein the alkylphosphocholine further comprises an alkyl chain of ten to twenty methylene groups.

CONFIDENTIAL

5

2

10